sector medic suppli devic
ew set stage anoth strong
growth year rais pt reiter buy
messag edward deliv impress result ep yoy
come consensu revenu organ beat
driven upsid across three compani segment back
perform manag rais outlook laid week ago
tavr market continu allay concern slow growth strong cadenc
new product launch ahead next month believ edward
continu outperform pt goe reiter buy rate
tavr finish year strong domest tavr revenu
sequenti consensu driven strong growth lower volum hospit
need see result week know sure estim
 tavr market grew tavr revenu
cc also better expect come consensu sapien
ultra centera set launch europ quarter optimist edward
ou tavr busi continu deliv solid growth go forward compani
build view alreadi best-in-class product offer centera particularli
intrigu view give edward premium offer eu market
use self-expand valv today believ price sensit certain account
could limit compani opportun share gain fraction total model
mere assum stabil edward share go forward leav outright gain
sourc potenti upsid meanwhil eu tavr market continu grow
healthi clip sale rise ex-fx math combin strong
growth japan estim ww tavr revenu grew cc last year
expect growth slow view manag guidanc gain
potenti conserv backdrop
outsid transcathet valv edward surgic valv critic
busi sourc upsid heart valv therapi revenu rose cc
consensu edward aortic valv volum continu feel
pressur rise tavr penetr sale benefit on-going posit mix
shift continu roll-out inspiri resilia valv europ
resilia launch kick last month entri japan still slate later year
pend reimburs approv continu believ ramp tavr adopt
repres headwind eventu appli signific pressur surgic valv
busi remain encourag edward abil innov tri stay ahead
wave long possibl manag expect sale
come high end prior guidanc rang impli underli
growth model call revenu cc
elsewher critic system sale rose cc top consensu
driven strength edward enhanc surgic recoveri esr product
line china recent launch hemospher next-gen advanc
monitor platform also upsid driver quarter roll-out set ramp
throughout manag expect sale come high end
initi guidanc rang well underli forecast call
revenu cc
continu page
page analyst certif import disclosur
top line lower spend help off-set weak gross margin allow
revenu upsid fall edward report gross margin
yoy consensu posit product mix partial off-set
fx hedg expens relat closur compani swiss manufactur
facil sg spend fell yoy came street
expect expens increas sale
consensu combin drove ebita margin solid yoy
shi street project
one month year guidanc alreadi move higher conjunct
releas edward rais outlook adjust ep
combin lower tax rate post reform improv
oper perform increas midpoint two rang
estim tax chang account fx ad anoth
upgrad tavr outlook contribut remain meanwhil manag
expect total revenu high end rang model
call adjust ep total revenu organ
prior estim respect
long-term confid edward growth runway remain unchang
compani enter strong momentum steadi cadenc new product
tr eu ultra tap sustain move year
resili tavr market continu allay concern slow growth even
cross mark competit landscap effect de-risk next
month like expans low risk popul wait see edward
well-posit continu outperform rais dcf-deriv
price target signific upsid potenti target current
level reiter buy rate ew share
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track least doubl next five year edward pois primari
beneficiari growth even competit increas meanwhil compani robust
pipelin potenti extend growth runway well next decad view
emerg opportun expand tavr applic beyond sever
symptomat aortic stenosi popul develop equal compel new market
transcathet treatment mitral tricuspid valv diseas visibl new
growth driver improv expect investor confid edward long-term growth
potenti increas support premium valuat stock
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat also make
compani difficult valu base tradit metric result employ
discount cash flow methodolog deriv price target assum
wacc termin growth rate calcul forward npv per share
previous equat multipl forward ntm
ep estim signific upsid potenti price target current level
assign edward buy rate
downsid risk rate price target includ tavr market growth fall
short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
